Industry Briefs: Mar. 19, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: Mar. 19, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Bend Reasearch has launched a biotherapeutics-development initiative. Read More

OctoPlus has formed an agreement with a top-five generic-drugs company for the development of a formulation for an injectable drug. Read More

QRxPharma has signed a license and option agreement with Actavis. Read More

Recipharm has been contracted by ViroPharma to complete a full commercial scale-up manufacture of DuoCort’s Plenadren (hydrocortisone modified-release tablet). Read More

Shire plans to acquire FerroKin BioSciences for an upfront payment of $100 million. Read More

ThromboGenics has formed a commercialization agreement for Ocriplasmin with Alcon. Read More

People News

Stuart E. Needleman has been named president and chief operating officer of Aptuit, effective immediately. Read More

Avanir Pharmaceuticals has appointed Rohan Palekar as chief commercial officer. Read More

Unigene has appointed David Moskowitz as chief financial officer. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here